相关实验视频
Updated: Jun 14, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
综合战略,以支持糖尿病技术在怀孕期间
Laura M Nally1, Julia E Blanchette
1Yale University School of Medicine, New Haven, Connecticut; and the School of Medicine, Case Western Reserve University, Cleveland, Ohio.
Obstetrics and gynecology
|August 29, 2024
概括
像连续血糖监测器这样的糖尿病技术可以改善怀孕护理,但访问是有限的. 本次审查强调了安全和公平地为孕妇实施这些工具的好处和支持.
科学领域:
- 生殖内分泌学和糖尿病管理.
背景情况:
- 怀孕涉及显著的生理变化,需要勤奋的糖尿病管理.
- 糖尿病技术的进步改善了1型糖尿病患者的治疗结果.
- 在怀孕期间获得糖尿病技术的机会并没有跟上进步.
研究的目的:
- 审查持续血糖监测器 (CGM) 和自动胰岛素输送系统 (AID) 在怀孕中的好处.
- 突出在怀孕期间实施糖尿病技术的科学和结构支持.
主要方法:
- 关于怀孕期间糖尿病技术的当前文献的综述.
- 分析CGM和AID系统在孕期使用的好处和挑战.
- 确定安全,有效和公平实施的战略.
主要成果:
- CGM和AID系统为糖尿病孕妇的血糖控制和生活质量提供了显著的好处.
- 目前的监管和访问障碍限制了这些技术在怀孕期间的广泛采用.
- 需要针对科学和结构支持提出具体建议.
结论:
- 在怀孕期间实施先进的糖尿病技术对于改善母亲和胎儿的结果至关重要.
- 解决监管和获取问题对于公平的护理至关重要.
- 需要进一步的研究和政策变化,以支持在整个怀孕期间安全有效地使用糖尿病技术.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Pathophysiology of Diabetes
908
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
908
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178

